Menu
Menu
842133-18-0
Anti-Diabetic
C24H25FO5S
444.5 g/mol
Amorphous
Commercial
Ready
Ready
Canagliflozin is an anti-diabetic drug, falling under the class of blood glucose lowering drugs. It is used to lower blood sugar levels and reduce the risk of heart attack, stroke, or death in adults with type 2 diabetes mellitus. It reduces the risk of end-stage kidney disease, worsening of kidney function, needing to be hospitalized for heart failure, and cardiovascular death in people who have type 2 diabetes along with severe kidney disease. Canagliflozin can be used as monotherapy or in combination with other glucose lowering medicines. Canagliflozin is administered through oral route by way of film-coated tablets.
Canagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used for the improvement of glycaemic control in type 2 diabetes. SGLT2 is the main transporter that mediates reabsorption of glucose in the kidneys, from the glomerular filtrate back into the circulation. Canagliflozin improves glycaemic control by competitively inhibiting SGLT2, thereby reducing renal glucose reabsorption. Canagliflozin inhibits SGLT2, thereby lowering reabsorption of filtered glucose into the body and decreasing the renal threshold for glucose (RTG), leading to increased glucose excretion in the urine.
Ornet Pharmaceuticals, based out of Gujarat, India, is a leading manufacturer and global supplier of Canagliflozin API. Driven by technically sound, research-oriented leaders, each with over 2 decades of hands-on experience, Ornet develops and manufactures a wide array of complex APIs catering to multiple categories in its product portfolio, such as anti-diabetics, blood related, hormones, etc. Ornet’s Canagliflozin API is the result of the “Quality over Quantity” approach taken by the organization for all R&D and manufacturing practices. This approach, along with the strategically located manufacturing facility in Gujarat, allows for Ornet to be a primary source, both domestically and globally, for all API needs.
Products protected by valid patents are not offered for commercial sale in countries where the sale of such products constitutes patent infringement but are offered solely for uses reasonably related to the development and submission of information under a law regulating the manufacture, use or sale of drugs. It is within the buyer’s responsibility and liability to check the patent situation of the product in the imported market(s).
